Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Wright Reports
$75.00
Provider: Reuters Investment Profile
$20.00
Provider: Sadif Analytics Prime
$10.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Shanghai Fudan-zhangjiang Bio-Pharmaceutical Co Ltd gives FY 2013 earnings guidance


Monday, 10 Feb 2014 03:46am EST 

Shanghai Fudan-zhangjiang Bio-Pharmaceutical Co Ltd:Expects to record a substantial increase in profits for FY 2013 as compared to FY 2012.Such increase in profits is mainly attributable to the significant increase in the company's sales during such period.Based on the management accounts of the group, which have not been confirmed nor audited by the company‚Äôs auditors.FY 2013 net income of $124.49 mln - Thomson Reuters I/B/E/S. 

Latest Developments for Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd

Company Quote